循环内皮细胞在恩度联合NP方案治疗非小细胞肺癌中的变化及意义
2017-11-14杨宏韩震何敏张翠英
杨宏 韩震 何敏 张翠英

【摘要】 目的:探討肺癌患者恩度联合NP方案化疗前后外周血循环内皮细胞(CECs)以及活性循环内皮细胞(aCECs)的变化及其临床意义。方法:用流式细胞仪对2013年5月-2015年10月本院20例健康人(对照组)及68例肺癌患者(治疗组)治疗前后外周血CECs及aCECs进行检测。结果:对照组外周血CECs及aCECs的数量均低于治疗组,差异均有统计学意义(P<0.001)。恩度联合NP治疗后CECs及aCECs数目出现分层变化,其中临床获益(CR+PR)患者CECs及aCECs数目与治疗前比较,差异均有统计学意义(P<0.001);临床进展(PD)患者CECs及aCECs数目与治疗前比较,差异均无统计学意义(P>0.05);临床稳定(SD)患者CECs及aCECs数目变化分层、CECs数目变化与治疗前比较,差异均无统计学意义(P>0.05),aCECs数目与治疗前比较,差异有统计学意义(P<0.05)。结论:恩度通过对肿瘤血管生成的负性调节,提高了抗肿瘤效果并抑制肿瘤生长速度,CECs及aCECs的联合检测可能是恩度联合NP方案治疗肺癌的较好疗效预测指标。
【关键词】 恩度; 循环内皮细胞; 活化循环内皮细胞
The Changes and Significance of Circulating Endothelial Cells in Non-small Cell Lung Cancer Treatment of Endostar Combined with NP Regimen/YANG Hong,HAN Zhen,HE Min,et al.//Medical Innovation of China,2017,14(27):023-026
【Abstract】 Objective:To discuss the changes of endothelial cells(CECs) in peripheral blood circulation(CECs) and the changes of the active circulating endothelial cells(aCECs) and its clinical significance in patients with lung cancer patients.Method:CECs and aCECs were detected in 20 healthy people (the control group)and 68 lung cancer patients(the treatment group)by flow cytometry before and after treatmnet from June 2013 to October 2015.Result:The number of CECs and aCECs in control group were significantly lower than those of the treatment group,the differences were statistically significant(P<0.001). Endostar combined with NP after the treatment of CECs and the number of aCECs layered changes,the number of CECs and aCECs in patients with clinical benefit(CR+PR) were decreased than before treatment,the differences were statistically significant(P<0.001),there were no significant differences of the number of CECs and aCECs in patients with clinical progress(PD) before and after treatment(P>0.05).The number of CECs and aCECs in patients with clinical stability(SD) was stratified,and there were no significant differences CECs before and after treatment(P>0.05),and the differences of aCECs number before and after treatment was statistically significant(P<0.05).Conclusion:Endostar can improve anti-tumor therapeutic effect and inhibit tumor growth speed by negative regulation of tumor angiogenesis, the combined detection of CECs and aCECs may be a good predictor to evaluate the Endostar combined with NP chemotherapy in patients with lung cancer.
【Key words】 Endu; Circulating endothelial cells; Activated circulating endothelial cells
First-authors address:Inner Mongolia Peoples Hospital,Hohhot 010017,Chinaendprint
doi:10.3969/j.issn.1674-4985.2017.27.007
非小細胞肺癌(Non-small cell lung cancer)是肺癌的特发病例,也是肺癌患者中占据比例较大的疾病类型,临床统计数据显示,其占肺癌总数的75%~85%,且诊断难度较大[1]。恩度(Endostar)是我国自主设计研发的抗新生血管生成疗法,治疗机制以建立足够的血管系统,从而为其生长提供氧气和营养为目标,对抑制血管生成和肿瘤生长具有遏制作用[2]。恩度联合化疗成为NSCLC一线治疗非小细胞肺癌的可行性方案[3]。但是恩度价格很高而且有一定的副反应,因此有必要寻找一种方法来预测其疗效,从而可以指导临床选择减少患者不必要的经济负担的方案,真正做到精准治疗。抗血管生成药物通过抑制VEGF-VEGFR途径来抑制血管内皮细胞特异性生长。是调节血管生成细胞因子、诱导血管新生和抑制肿瘤生长方面起着重要作用,国外学者研究发现它能在体内诱导血管新生、反映肿瘤血管生成及监测血管治疗药物疗效的标记物[4]。其中……
